4 analysts have shared their evaluations of CVRx (NASDAQ:CVRX) during the recent three months, expressing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 1 | 0 | 1 | 0 |
| Last 30D | 0 | 1 | 0 | 1 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 2 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $12.75, along with a high estimate of $18.00 and a low estimate of $7.00. Experiencing a 33.77% decline, the current average is now lower than the previous average price target of $19.25.
Analyzing Analyst Ratings: A Detailed Breakdown
A clear picture of CVRx's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Matt O'Brien | Piper Sandler | Lowers | Overweight | $12.00 | $20.00 |
| Robbie Marcus | JP Morgan | Lowers | Underweight | $7.00 | $15.00 |
| Frank Takkinen | Lake Street | Lowers | Buy | $14.00 | $19.00 |
| William Plovanic | Canaccord Genuity | Lowers | Buy | $18.00 | $23.00 |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to CVRx. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of CVRx compared to the broader market.
- Price Targets: Delving into movements, analysts provide estimates for the future value of CVRx's stock. This analysis reveals shifts in analysts' expectations over time.
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of CVRx's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on CVRx analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Discovering CVRx: A Closer Look
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
CVRx: Delving into Financials
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: CVRx's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 35.71%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: CVRx's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -69.42%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): CVRx's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -15.64% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -8.16%, the company showcases effective utilization of assets.
Debt Management: CVRx's debt-to-equity ratio is below the industry average at 0.71, reflecting a lower dependency on debt financing and a more conservative financial approach.
Understanding the Relevance of Analyst Ratings
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.